Publications



Results 1-41 of 41 (Search time: 0.082 seconds).

Issue DateTitleAuthor(s)SourcescopusWOSFulltext/Archive link
12022Tumor-Derived C-C Motif Ligand 2 Induces the Recruitment and Polarization of Tumor-Associated Macrophages and Increases the Metastatic Potential of Bladder Cancer Cells in the Postirradiated MicroenvironmentYUN CHIANG ; YU-CHIEH TSAI ; Wang, Chung-Chieh; FU-JEN HSUEH ; Huang, Chao-Yuan; Chung, Shiu-Dong; Chen, Chung-Hsin; Pu, Yeong-Shiau; Cheng, Jason Chia-HsienInternational journal of radiation oncology, biology, physics1
22022The risk of subsequent malignancies in patients with renal cell carcinoma: A nationwide, population-based studyLu, Yu Cheng; YU-CHIEH TSAI ; Po-Ming Chow; Weng, Wen Ching; Huang, Wei Yi; Chueh, Shih Chieh; Kao-Lang Liu; Kuo-How HuangUrological Science0
32021Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinomaYang S.-Y.; Wang C.-C.; Chen K.-D.; Liu Y.-W.; Lin C.-C.; Chuang C.-H.; YU-CHIEH TSAI ; Yao C.-C.; Yen Y.-H.; Hsiao C.-C.; Hu T.-H.; Tsai M.-C.BMC Cancer44
42021Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resectionYU-CHIEH TSAI ; Sou F.-M.; Liu Y.-W.; Wu Y.-J.; Yong C.-C.; Chen D.-W.; Huang P.-Y.; Cho W.-R.; Chuang C.-H.; Hsiao C.-C.; Hu T.-H.; Tsai M.-C.BMC Gastroenterology12
52020Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialPowles T.; van der Heijden M.S.; Castellano D.; Galsky M.D.; Loriot Y.; Petrylak D.P.; Ogawa O.; Park S.H.; Lee J.-L.; De Giorgi U.; B?gemann M.; Bamias A.; Eigl B.J.; Gurney H.; Mukherjee S.D.; Fradet Y.; Skoneczna I.; Tsiatas M.; Novikov A.; Su?rez C.; Fay A.P.; Duran I.; Necchi A.; Wildsmith S.; He P.; Angra N.; Gupta A.K.; Levin W.; Bellmunt J.; van der Heijden M.S.; Lee J.L.; Eigl B.J.; Mukherjee S.D.; Suarez C.; Westgeest H.; Flechon A.; Ou Y.-C.; Park I.; Matveev V.; P?rez-Valderrama B.; Cheng S.; Frank S.; Anido U.; Hamzaj A.; Retz M.; Sridhar S.; Scagliotti G.V.; Voortman J.; Alekseev B.; Alyasova A.; Komyakov B.; Dumez H.; Pavic M.; Kimura G.; Mizokami A.; Osanto S.; Arranz J.A.; Piersma D.; Shin S.J.; Karyakin O.; Delgado I.; Gonzalez J.L.; Pang S.-T.; Tran A.; Lipatov O.; Su W.-P.; Flaig T.; Alva A.; Park Kyong H.; Kopyltsov E.; Almagro E.; Domenech M.; Chang Y.-H.; Sautois B.; Ravaux A.; Aravantinos G.; Georgoulias V.; Mulder S.; Kim Y.J.; Kater F.; Chevreau C.; Tagawa S.; Zalewski P.; Joly F.; Hatiboglu G.; Gianni L.; Morelli F.; Tambaro R.; Hashimoto Y.; Nosov A.; Font A.; Rodriguez-Vida A.M.; Jones R.; Vasudev N.; Srinivas S.; Zhang J.; Gil T.; Finch D.; Grimm M.-O.; Su Y.-L.; Chowdhury S.; Hocking C.; Plas E.; North S.; Jensen N.V.; Theodore C.; Imkamp F.; Peer A.; Kobayashi T.; Sakai H.; Sassa N.; Yoshimura K.; Aarts M.; Ferreira Castro A.; Topuzov M.; Rodriguez J.F.; Vazquez F.J.; YU-CHIEH TSAI ; Crabb S.; Hussain S.; Bendell J.; Gross-Goupil M.; Gwenaelle G.; Berger R.; Statsenko G.; Evans L.; Drakaki A.; Somer B.; Davis I.; Lynam J.; Borges G.; Dettino A.; Fay A.P.; Martins G.; Zucca L.E.; Agerbaek M.; Kalofonos H.; Rosenbaum E.; Enokida H.; Kikukawa H.; Nishimura K.; Tamada S.; Uemura M.; Lopez Y.; Gietema J.; Slojewski M.; Fernandes I.; Smolin A.; Mazhar D.; Kalebasty A.R.; Carthon B.; Loidl W.; Franke F.; Girotto G.; Alimohamed N.; Macfarlane R.; Pappot H.; Niegisch G.; Mavroudis D.; Sella A.; Porta C.; Ebara S.; Nakamura M.; Obara W.; Okuno N.; Shinohara N.; Sugimoto M.; Suzuki A.; Tokuda N.; Uemura H.; Yamaguchi A.; Ramirez F.; Rozanowski P.; Wiechno P.; Keam B.; Kislov N.; Plaksin D.; Cicin I.; Kumar S.; Galsky M.D.; Petrylak D.P.; Rosales J.; Vaishampayan U.; Culine S.; Papandreou C.; Nara T.; Erman M.; Kreiger L.; Janoski J.; Rosa D.; Siqueira M.; Canil C.; Sengelov L.; Tourani J.-M.; Arai G.; Hashine K.; Kawakita M.; Nakaigawa N.; Nomi H.; Shiina H.; Suzuki H.; Yonese J.; Kuri R.; Macedo E.; Rivera S.; Villalobos Prieto A.; Polakiewicz-Gilowska A.; Zaucha R.; Lopes F.; Ponomarev R.; Pomerantz M.; Shariat S.; Luk C.; Lesniewski-Kmak K.The Lancet Oncology146136
62020Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cellsTien Y.; Tsai C.-L.; Hou W.-H.; Chiang Y.; Hsu F.-M.; YU-CHIEH TSAI ; Cheng J.C.-H.Radiation Oncology23
72020Current and future aspect of immunotherapy for advanced renal cell carcinomaHsueh F.-J.; YU-CHIEH TSAI Urological Science22
82020Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasionChen J.; Sun Y.; Ou Z.; Yeh S.; Huang C.-P.; You B.; YU-CHIEH TSAI ; Sheu T.-J.; Zu X.; Chang C.EMBO Reports4041
92020Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgeryCho W.-R.; Hung C.-H.; Chen C.-H.; Lin C.-C.; Wang C.-C.; Liu Y.-W.; Wu Y.-J.; Yong C.-C.; Chen K.-D.; YU-CHIEH TSAI ; Hu T.-H.; Tsai M.-C.Scientific Reports119
102019Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma (Journal of Molecular Medicine, (2018), 96, 12, (1307-1318), 10.1007/s00109-018-1697-7)Lin W.-C.; Hsu F.-S.; Kuo K.-L.; Liu S.-H.; Shun C.-T.; Shi C.-S.; Chang H.-C.; YU-CHIEH TSAI ; Lin M.-C.; Wu J.-T.; Kuo Y.; Chow P.-M.; Liao S.-M.; Yang S.-P.; Hong J.-Y.; Huang K.-H.Journal of Molecular Medicine11
112019Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinomaGuo J.-C.; YU-CHIEH TSAI ; Pu Y.-S.Urological Science00
122019Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancerWang C.-C.; YU-CHIEH TSAI ; Jeng Y.-M.PLoS ONE2421
132019Nuclear factor-�eB overexpression is correlated with poor outcomes after multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancerChiang Y.; Wang C.-C.; YU-CHIEH TSAI ; Huang C.-Y.; Pu Y.-S.; Lin C.-C.; Cheng J.C.-H.Journal of Clinical Medicine21
142018Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinomaLin W.-C.; Hsu F.-S.; Kuo K.-L.; Liu S.-H.; Shun C.-T.; Shi C.-S.; Chang H.-C.; YU-CHIEH TSAI ; Lin M.-C.; Wu J.-T.; Kuo Y.; Chow P.-M.; Liao S.-M.; Yang S.-P.; Hong J.-Y.; Huang K.-H.Journal of Molecular Medicine67
152017Effects of short forest bathing program on autonomic nervous system activity and mood states in middle-aged and elderly individualsYu C.-P.; Lin C.-M.; Tsai M.-J.; YU-CHIEH TSAI ; Chen C.-Y.International Journal of Environmental Research and Public Health8672
162017Preliminary evidence of polymorphisms of cell cycle regulatory genes and their roles in urinary tract urothelial cancer susceptibility and prognosis in a Taiwan populationLin Y.-C.; Hour T.-C.; YU-CHIEH TSAI ; Huang S.-P.; Wu W.-J.; Chen C.-H.; Pu Y.-S.; Chung S.-D.; Huang C.-Y.Urologic Oncology: Seminars and Original Investigations1110
172017A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvementChiang Y.; Cheng J.C.-H.; Huang C.-Y.; YU-CHIEH TSAI ; Lin C.-C.; Hsu C.-H.; Cheng A.-L.; Pu Y.-S.Journal of the Formosan Medical Association76
182017CCN3 promotes epithelial-mesenchymal transition in prostate cancer via FAK/Akt/HIF-1�\-induced twist expressionChen P.-C.; Tai H.-C.; Lin T.-H.; Wang S.-W.; Lin C.-Y.; Chao C.-C.; Yu H.-J.; YU-CHIEH TSAI ; Lai Y.-W.; Lin C.-W.; Tang C.-H.Oncotarget1211
192016Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinomaHsu F.-M.; Hou W.-H.; Huang C.-Y.; Wang C.-C.; Tsai C.-L.; YU-CHIEH TSAI ; Yu H.-J.; Pu Y.-S.; Cheng J.C.-H.Chronobiology International2325
202015Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cellsYU-CHIEH TSAI ; Ho P.-Y.; Tzen K.-Y.; Tuan T.-F.; Liu W.-L.; Cheng A.-L.; Pu Y.-S.; Cheng J.C.-H.Molecular Cancer Therapeutics2121
212015MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studiesKuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; YU-CHIEH TSAI ; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; Pu Y.-S.; Huang K.-H.Cancer Letters4345
222015Ureteral involvement and diabetes increase the risk of subsequent bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinomaHu C.-Y.; YU-CHIEH TSAI ; Wang S.-M.; Huang C.-Y.; Tai H.-C.; Chen C.-H.; Pu Y.-S.; Lin W.-C.; Huang K.-H.BioMed Research International73
232015MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinomaHo I.-L.; Kuo K.-L.; Liu S.-H.-.; Chang H.-C.; Hsieh J.-T.; Wu J.-T.; Chiang C.-K.; Lin W.-C.; YU-CHIEH TSAI ; Chou C.-T.; Hsu C.-H.; Pu Y.-S.; Shi C.-S.; Huang K.-H.Scientific Reports3030
242014Estrogen receptor alpha prevents bladder cancer development via INPP4B inhibited Akt pathway in vitro and in vivoHsu I.; Yeh C.-R.; Slavin S.; Miyamoto H.; Netto G.J.; YU-CHIEH TSAI ; Muyan M.; Wu X.-R.; Messing E.M.; Guancial E.A.; Yeh S.Oncotarget5349
252014Osteoblast-derived WISP-1 increases VCAM-1 expression and enhances prostate cancer metastasis by down-regulating miR-126Tai H.-C.; Chang A.-C.; Yu H.-J.; Huang C.-Y.; YU-CHIEH TSAI ; Lai Y.-W.; Sun H.-L.; Tang C.-H.; Wang S.-W.Oncotarget4541
262013Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinomaYU-CHIEH TSAI ; Yeh C.-H.; Tzen K.-Y.; Ho P.-Y.; Tuan T.-F.; Pu Y.-S.; Cheng A.-L.; Cheng J.C.-H.European Journal of Cancer2422
272012Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblastsYu S.; Yeh C.-R.; Niu Y.; Chang H.-C.; YU-CHIEH TSAI ; Moses H.L.; Shyr C.-R.; Chang C.; Yeh S.Prostate5248
282012The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cellsXu D.; Lin T.-H.; Zhang C.; YU-CHIEH TSAI ; Li S.; Zhang J.; Yin M.; Yeh S.; Chang C.Prostate1817
292012Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cellsHuang K.-H.; Kuo K.-L.; Chen S.-C.; Weng T.-I.; Chuang Y.-T.; YU-CHIEH TSAI ; Pu Y.-S.; Chiang C.-K.; Liu S.-H.PLoS ONE2924
302012Down-regulation of PKC�a in renal cell carcinoma and its clinicopathological implications.Pu Y.S.; Huang C.Y.; Chen J.Y.; Kang W.Y.; Lin Y.C.; Shiu Y.S.; Chuang S.J.; Yu H.J.; Lai M.K.; YU-CHIEH TSAI ; Wu W.J.; Hour T.C.Journal of biomedical science1512
312011Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinomaHsu F.-M.; Lee J.-M.; Huang P.-M.; Lin C.-C.; Hsu C.-H.; YU-CHIEH TSAI ; Lee Y.-C.; Chia-Hsien Cheng J.International Journal of Radiation Oncology Biology Physics3635
322009Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder CancerLin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; YU-CHIEH TSAI ; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; Pu Y.-S.International Journal of Radiation Oncology Biology Physics2318
332009Down regulation of ABCD1 in human renal cell carcinomaHour T.-C.; Kuo Y.-Z.; Liu G.-Y.; Kang W.-Y.; Huang C.-Y.; YU-CHIEH TSAI ; Wu W.-J.; Huang S.-P.; Pu Y.-S.International Journal of Biological Markers99
342009Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomyHsu F.-M.; Lee Y.-C.; Lee J.-M.; Hsu C.-H.; Lin C.-C.; YU-CHIEH TSAI ; Wu J.-K.; Cheng J.C.-H.Annals of Surgical Oncology3231
352008Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized studyHsu F.-M.; Lin C.-C.; Lee J.-M.; Chang Y.-L.; Hsu C.-H.; YU-CHIEH TSAI ; Lee Y.-C.; Cheng J.C.-H.Journal of Surgical Oncology3028
362007Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancerChen C.-H.; Shun C.-T.; Huang K.-H.; Huang C.-Y.; YU-CHIEH TSAI ; Yu H.-J.; Pu Y.-S.BJU International9082
372007Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinomaLin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; YU-CHIEH TSAI ; Hsu W.-L.; Cheng A.-L.; Hsu C.-H.Anti-Cancer Drugs108
382007Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based RegimensLin C.-C.; Hsu C.-H.; Huang C.-Y.; YU-CHIEH TSAI ; Huang K.-H.; Cheng A.-L.; Pu Y.-S.Urology2018
392007Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II studyLin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; YU-CHIEH TSAI ; Huang K.-H.; Cheng A.-L.; Pu Y.-S.Anti-Cancer Drugs3229
402005Response of refractory osteosarcoma to thalidomide and celecoxibYU-CHIEH TSAI ; Wu C.-T.; Hong R.-L.Lancet Oncology1514
412002Osteonecrosis of the femoral head in a human immunodeficiency virus type 1-infected patient with lipodystrophyYU-CHIEH TSAI ; Liu C.-H.; Liao C.-H.; Chen M.-Y.; Hung C.-C.Journal of the Formosan Medical Association45